PBH

DA Davidson Upgrades Prestige Consumer Healthcare (PBH)

Fintel reports that on June 21, 2024, DA Davidson upgraded their outlook for Prestige Consumer Healthcare (NYSE:PBH) from Neutral to Buy.

Analyst Price Forecast Suggests 9.64% Upside

As of June 12, 2024, the average one-year price target for Prestige Consumer Healthcare is 76.09. The forecasts range from a low of 65.65 to a high of $85.05. The average price target represents an increase of 9.64% from its latest reported closing price of 69.40.

See our leaderboard of companies with the largest price target upside.

The projected annual revenue for Prestige Consumer Healthcare is 1,174MM, an increase of 4.32%. The projected annual non-GAAP EPS is 4.69.

What is the Fund Sentiment?

There are 672 funds or institutions reporting positions in Prestige Consumer Healthcare. This is an increase of 8 owner(s) or 1.20% in the last quarter. Average portfolio weight of all funds dedicated to PBH is 0.25%, an increase of 3.50%. Total shares owned by institutions increased in the last three months by 0.55% to 64,742K shares. PBH / Prestige Consumer Healthcare Inc. Put/Call Ratios The put/call ratio of PBH is 0.39, indicating a bullish outlook.

What are Other Shareholders Doing?

PBH / Prestige Consumer Healthcare Inc. Shares Held by Institutions

IJR - iShares Core S&P Small-Cap ETF holds 3,357K shares representing 6.73% ownership of the company. In its prior filing, the firm reported owning 3,319K shares , representing an increase of 1.14%. The firm increased its portfolio allocation in PBH by 14.83% over the last quarter.

Macquarie Group holds 2,920K shares representing 5.85% ownership of the company. In its prior filing, the firm reported owning 3,063K shares , representing a decrease of 4.89%. The firm decreased its portfolio allocation in PBH by 5.04% over the last quarter.

Ariel Investments holds 2,561K shares representing 5.13% ownership of the company. In its prior filing, the firm reported owning 2,556K shares , representing an increase of 0.20%. The firm decreased its portfolio allocation in PBH by 51.02% over the last quarter.

Victory Capital Management holds 1,903K shares representing 3.81% ownership of the company. In its prior filing, the firm reported owning 674K shares , representing an increase of 64.56%. The firm increased its portfolio allocation in PBH by 163.82% over the last quarter.

DCCAX - Delaware Small Cap Core Fund holds 1,686K shares representing 3.38% ownership of the company. In its prior filing, the firm reported owning 1,692K shares , representing a decrease of 0.41%. The firm increased its portfolio allocation in PBH by 11.72% over the last quarter.

Prestige Consumer Healthcare Background Information
(This description is provided by the company.)

Prestige Consumer Healthcare markets, sells, manufactures and distributes consumer healthcare products to retail outlets throughout the U.S. and Canada, Australia, and in certain other international markets. The Company's diverse portfolio of brands include Monistat® and Summer's Eve® women's health products, BC® and Goody's® pain relievers, Clear Eyes® eye care products, DenTek® specialty oral care products, Dramamine® motion sickness treatments, Fleet® enemas and glycerin suppositories, Chloraseptic® and Luden's® sore throat treatments and drops, Compound W® wart treatments, Little Remedies® pediatric over-the-counter products, Boudreaux's Butt Paste® diaper rash ointments, Nix® lice treatment, Debrox® earwax remover, Gaviscon® antacid in Canada, and Hydralyte® rehydration products and the Fess® line of nasal and sinus care products in Australia.

Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.

Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.

Click to Learn More

This story originally appeared on Fintel.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Tags

More Related Articles

Info icon

This data feed is not available at this time.

Sign up for the TradeTalks newsletter to receive your weekly dose of trading news, trends and education. Delivered Wednesdays.